

## SPONSORSHIP AGREEMENT



Parties to this agreement:

### Danmarks Bløderforening

Att.: Karen Binger Holm  
Blekinge Boulevard 2  
2630 Taastrup  
CVR No. 11802990

("Recipient")

### Novo Nordisk Denmark A/S

Att.: Christian Klyver Tikkanen  
Kay Fiskers Plads 10, 6 floor  
2300 København S  
CVR No. 38180045

("Novo Nordisk")

## 1. Summary

**1.1 Recipient's request for support.** The appendix titled "Recipient's request for support" details the specifics of the Recipient's activity(ies) ("the Activity") supported by the sponsorship and purpose of the Activity.

<b>Title of Activity</b>	Bløderforeningens Årsmøde 2025
<b>The Sponsorship</b>	<p>Novo Nordisk will provide 48.750 DKK, including added tax if applicable to support the Recipient's request.</p> <p>Novo Nordisk will not make any non-financial transfers of value.</p> <p>In exchange for the sponsorship, the Recipient shall provide to Novo Nordisk the tangible benefit of: We will be mentioned both at the annual meeting to all participants, as well as accredited in the Haemophilia Society's Newspaper with our logo and name.</p> <p>Novo Nordisk is one of several sponsors of the activity.</p>
<b>Agreement Duration</b>	This agreement starts on 26 April 2025 and expires after all obligations are fulfilled, unless terminated earlier.

## 2. Recipient's Duties

**2.1 Compliance with law and ethics.** The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

**2.2 Carry out the Activity with proper conduct.** The Recipient shall carry out the Activity independently and in compliance with Novo Nordisk standards and industry codes, in Denmark called ENLI (Etisk nævn for lægemiddelindustrien).

<b>No use of funds for entertainment</b>	Do not use the sponsorship for leisure or social activities
<b>Select qualified participants</b>	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity

Sponsorship Agreement, DK, 2022-DEC

Local Adaptation of HQ Sponsorship Agreement v2

July 2021

<b>Reasonable payment and awards</b>	<p>If sponsorship is used for awards or other payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients.</p> <p>Novo Nordisk support shall not go towards any gifts. Any support to honoraria shall be monetary only. Novo Nordisk funding cannot be used for C. in the budget.</p>
<b>Reasonable choice of venue</b>	<p>Hold activities in a location suitable for the Activity with modest hospitality.</p>
<b>Reasonable travel</b>	<p>If sponsorship is used for Activity-related travel, carry out within reasonable time and cost.</p> <p>Novo Nordisk will only accept support to compensation of mileage to Health Care Professionals that follows ENLI's (Etisk Nævn for Lægemedelindustrien) tariffs, ref. to §13, 7 in ENLI's Promotion Code. Support that goes towards compensation of car mileage as according to the state tariffs is not permitted.</p> <p>Novo Nordisk funding cannot be used for B. in the budget.</p>
<b>Transparency about support towards participants</b>	<p>The invitation for the event must clearly state that the event is being sponsored by one or more pharmaceutical companies.</p>
<b>No access for the general public</b>	<p>The commercial area with promotional booths will not be accessible for the general public; only health care professionals can have access to this area.</p>
<b>Acknowledgment of obligations towards ENLI</b>	<p>The Recipient acknowledges that Novo Nordisk must report the sponsorship to ENLI (Etisk Nævn for Lægemedelindustrien) in accordance with ENLI's Promotion Code.</p>
<b>Acknowledgement of obligations towards Danish Medicines Agency</b>	<p>If Danish doctors, nurses, midwives, dentists or pharmacists are affiliated with the activity and receive honorarium from the support provided by Novo Nordisk these persons must be informed about their obligation to report this affiliation to Danish Medicines Agency. The Recipient undertakes to fulfil this information duty and to give Novo Nordisk the following information: Name, authorisation ID, workplace, home address, affiliation start date, affiliation end date. Novo Nordisk must also report this information to the Danish Medicines Agency.</p>

**2.3 Physical items provided as-is.** If Novo Nordisk donates physical items, the Recipient is solely responsible for the use of such items, and shall assure proper handling and storage of sponsored items after delivery. Novo Nordisk is not liable for the Recipient's use of sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides such items as-is and without any representation or warranty of quality or performance.

**2.4 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the sponsorship.

**2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. If Novo Nordisk determines the change affects its compliance requirements, Novo Nordisk may demand full or partial return of sponsorship, at the discretion of Novo Nordisk. In the case of return, the Recipient shall comply within 14 days.

**2.6 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the sponsorship was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

**2.7 Disclose Novo Nordisk as sponsorship provider.** The Recipient shall mention Novo Nordisk as the provider of the sponsorship in any public communications or advertising related to the Activity.

**2.8 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

**2.9 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's sponsorship.

### 3. Requirements for Financial Sponsorships

**3.1 Payment after receipt of invoice.** Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: [AP-Novo-Repas@novonordisk.com](mailto:AP-Novo-Repas@novonordisk.com) and [CTIK@novonordisk.com](mailto:CTIK@novonordisk.com)

Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Sponsorship amount payable
- VAT or other tax amount payable
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient      Christian Klyver Tikkanen (CTIK)

**3.2 Refund unspent amounts.** The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

### 4. Other Terms and Conditions

**4.1 Require Public disclosures.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs"), Healthcare Organizations ("HCOs"), and Patient Organizations. In addition to the payment amount, such disclosure may also include Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

The Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

**4.2 No incentive to prescribe or recommend.** The sponsorship made by Novo Nordisk indicates no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.

**4.3 No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship and shall promptly inform Novo Nordisk if such conflict of interest is discovered.

**4.4 Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com/report-suspected-misconduct).

**4.5 Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.

**4.6 Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Attachments:

The following attachments are part of this agreement:

Attachment A: Recipient's request for support (application form, letter or email), with detailed program plan, timeline and budget

Attachment B: Sponsorships to Health Care Organizations and Patient Organizations: required public disclosures and handling of employee data

6. Agreed to and Accepted by:

Date: april 15, 2025

Date: April 11, 2025

On behalf of Recipient:

Signed by:



46A0A742616D4F7...

Name: Karen Binger Holm

Title: Sekretariatsleder

On behalf of Novo Nordisk:

DocuSigned by:



6086C4285774410...

Name: Christian Klyver Tikkanen

Title: Head of Market Access and Rare Disease

## Attachment A: Recipient's Request for Support

### 1. Copy of the Recipient's sponsorship request



Novo Nordisk

Taastrup d. 24. februar 2025

#### **Ansøgning om støtte til Danmarks Bløderforenings årsmøde 2025**

Med denne ansøgning søger Danmarks Bløderforening om støtte til afholdelse af foreningens årsmøde d. 26-27. april 2025 på Scandic, Ved Ringen 2, 4000 Roskilde.

Det samlede budget for arrangementet er 243.750 kr., hvor af foreningen søger om 48.750 kr. i støtte fra Novo Nordisk. Der søges om støtte fra flere firmaer, og et hvert bidrag modtages med tak.

Årsmødet er for alle foreningens medlemmer og sætter fokus på emner og problemstillinger, der går på tværs af medlemsgrupper og generationer.

Lørdag kommer overlæge Eva Funding fra Hæmofilcenter Rigshospitalet og deltager i "Hæmofililægens bord". Formatet giver mulighed for at komme godt rundt om, hvad der rør sig blandt deltagerne – lige fra spørgsmål om forhøjet blodtryk til nye behandlinger.

Formand Jacob Bech Andersen holder oplæg om livskvalitet set fra patientens perspektiv. Jacob stiller spørgsmålet, hvad er det gode bløderliv anno 2025 og deler både egne erfaringer og lægger op til diskussion blandt foreningens medlemmer. Der er lagt op til en god debat på tværs af medlemsskaren.

Søndag præsenteres Bløderforeningens nye vision 2025-2035, og programmet byder også på en inddragende visning, når børnene viser resultatet fra deres stomp-workshop.

I 2025 forventes 75 voksne og 20 børn at deltage. Program og budget er vedlagt ansøgningen.

Et hvert bidrag modtages med tak. Logo og firmanavn vil fremgå af endeligt program og støtten vil fremgå i forbindelse med omtale af årsmødet i nyhedsbreve og sociale medier.

Hvis der er spørgsmål til ansøgningen, står jeg naturligvis til rådighed og kan kontaktes på mail [kbh@bloderforeningen.dk](mailto:kbh@bloderforeningen.dk) eller +45 60246277.

Venlig hilsen  
Karen Binger Holm  
Sekretariatsleder

SE nr.: 11 80 29 90  
Sydbank, Reg. nr.: 7040, Konto nr.: 1106847

## 2. Activity timelines and budget

# PROGRAM

## LØRDAG

- **11.30-12.00:** Fælles velkomst v. bestyrelsen
- **12.00-13.00:** Frokost
- **13.00-14.30: Hæmofililægens bord:** Overlæge Eva Funding fra Hæmofilicenter Rigshospitalet samler op på mange af de spørgsmål, hun får fra bløderpatienter til daglig – lige fra tatoveringer, forhøjet blodtryk til nye behandlinger
- **14.30-15.00:** Fælles gåtur Ringen rundt
- **15.00-15.45:** Pause med kaffe og kage samt check ind
- **15.45-17.00: Det gode bløderliv?** Verdens sundeste bløderpatient... det er formand Jacob Bech Andersen på ingen måde. Men han har indset, at det gode liv for ham som kronisk bløderpatient også hænger sammen med parametre som livsstil, motion og sociale relationer. I dette oplæg, som er for alle aldre, kigger Jacob sin egen 50-årige bløderkrop efter i sømmene, lægger op til diskussion og stiller spørgsmålet: Hvad er det gode bløderliv anno 2025?
- **17.00-18.00:** Pause
- **18.00-19.30:** Fælles middag
- **19.30:** Underholdning for hele familien, aftenkaffe og hyggeligt samvær

Er du nyt medlem eller er det første gang, du skal med til årsmøde? Så starter programmet for dig lørdag kl. 11 med en introduktion



## SØNDAG

- **8.00-9.00:** Stikkerummet er åbent. Kom og prøv vores nye venescanner!
- **9.00-10.00:** Tour de Vision: Vi skal høre om foreningens nye vision for 2025-2035, og hvad der ellers sker i vores bløderverden
- **10.00-10.30:** Stomp v. børnene og stompinstruktør Peter Altmann
- **10.30-11.00:** Pause og check ud
- **11.00-13.00:** Generalforsamling
- **13.00:** Tak for denne gang og frokost to go

Danmarks Bløderforening  
Blekings Boulevard 2  
2630 Taastrup  
Tlf. 3314 5505  
www.bloderforeningen.dk



## Budget: Årsmøde 2025

Seminar for alle medlemmer og pårørende, 99 deltagere, 26.-27. april 2025, Scandic Roskilde

Udgift/navn		Budget		
Alle priser er inklusiv moms	<b>Antal</b>	<b>Sats pr.</b>	<b>Udgifter i alt</b>	<b>Noter</b>
		<b>time/stk./</b>	<b>kr.</b>	
Honorar oplægsholder	1	kr. 5.000	kr. 5.000	A
Transport, oplægsholder	Estimat		kr. 500	B
Honorar oplægsholder	1	kr. 1.000	kr. 1.000	C
Transport, oplægsholder	Estimat		kr. 500	B
Honorar, børnepassere	4	kr. 1.800	kr. 7.200	D
Transport, børnepassere	Estimat		2.000	B
Aktiviteter	Estimat		kr. 6.000	E
Diverse materialer	Estimat		kr. 1.000	F
Lokaler, forplejning og ophold	99	kr. 2.345	kr. 232.155	G
Porto	610	kr. 28	kr. 17.080	H
Deltagerbetaling	65/20	385/165	-kr. 28.685	I
Udgifter i alt			<b>kr. 243.750</b>	

### Noter

A) Oplægsholdere: Overlæge Eva Funding, Hæmofilicenter Rigshospitalet, holder oplæg og besvarer spørgsmål om blødersygdom, komorbiditet, forebyggelse og nye behandlinger

B) Estimat, kørsel i egen bil godtgøres efter statens takst, 2,23 kr. pr. km

C) Jacob Bech Andersen, Danmarks Bløderforening, holder oplæg om livskvalitet anno 2025

D) Fire børnepassere, honorar à 1.800 kr.

E) Interaktiv debat med Mentimeter + Stomp workshop og visning v. instruktør med fokus på rytme, bevægelse og fællesskab

F) Materialer til børneprogram

G) Ophold, forplejning og lokaleleje, Scandic Roskilde, 75 V, 20 B, 4 børnepassere

H) Udsendelse af årsmødeinvitation og kalender for aktiviteter i 2025

I) Voksne: 385 kr., børn: 165 kr. (bestyrelsesmedlemmer er undtaget)

SE nr.: 11 80 29 90  
Sydbank, Reg. nr.: 7040, Konto nr.: 1106847

## **Attachment B: Sponsorships to Health Care Organizations and Patient Organizations**

### **Transfer of Value Disclosure Appendix**

#### **WHY DO WE NEED TO COLLECT AND DISCLOSE YOUR INFORMATION?**

Novo Nordisk will collect your data and when required by law, disclose transfer of value provided to Healthcare professionals ("HCPs") and Healthcare Organizations ("HCOs") and Patient Organizations ("POs").

#### **YOUR INFORMATION - WHAT WE COLLECT FOR DISCLOSURE PURPOSES**

We collect your personal information (as defined in the list below) to comply with the applicable transparency requirements. This means that we will collect, and may disclose the following information:

Name

Address

Contact details

Nature of relationship with Novo Nordisk

Tax number or unique identifier

Any transfers of value and its payment details from us to you

#### **WHAT ARE YOUR OBLIGATIONS?**

If you share personal information about employees of your organisation with us, it is your obligation to inform the employees that their information has been shared with us and that they have been provided the right information as stated in applicable data protection laws including General Data Protection Regulation. Your organization is responsible for any losses caused to Novo Nordisk if the above obligation is not fulfilled.

#### **Notice of Personal Data Processing.**

Novo Nordisk is responsible for any processing of your personal data, as set out in the Notice of Personal Data Processing: <https://www.novonordisk.com/contact-us/external-support/external-commitments.html>. The version in force corresponds to the latest version before this agreement was signed. Follow the link for more information about how your data is collected, used, and protected, including your rights and who to contact with requests or concerns.